The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.
{iframe}https://scienceline.org/2018/11/first-crispr-clinical-trial-begins-in-europe/{/iframe}